Filing Details
- Accession Number:
- 0001564590-18-002066
- Form Type:
- 13G Filing
- Publication Date:
- 2018-02-14 16:03:36
- Filed By:
- Stasko Nathan
- Company:
- Novan Inc.
- Filing Date:
- 2018-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Nathan Stasko, Ph.D | 137,777 | 823,833 | 137,777 | 823,833 | 961,610 | 6.0% |
| Jeanie Stasko | 0 | 823,833 | 0 | 823,833 | 823,833 | 5.2% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Novan, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
66988N106
(CUSIP Number)
December 31, 2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13G
| CUSIP No. 66988N106 |
| Page 2 of 7 |
| (1) | Names of reporting persons
Nathan Stasko, Ph.D. | ||
| (2) | Check the appropriate box if a member of a group (see instructions)
(a) ☐ (b) ☐ | ||
| (3) | SEC use only
| ||
| (4) | Citizenship or place of organization
United States of America | ||
| Number of | (5) | Sole voting power
137,777 (1) | |
| shares beneficially owned by | (6) | Shared voting power
823,833 (2) | |
| each reporting person | (7) | Sole dispositive power
137,777 (1) | |
| with: | (8) | Shared dispositive power
823,833 (2) | |
| (9) | Aggregate amount beneficially owned by each reporting person
961,610 | ||
| (10) | Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
☐ | ||
| (11) | Percent of class represented by amount in Row (9)
6.0% (3) | ||
| (12) | Type of reporting person (see instructions)
IN | ||
|
| (1) | Includes options to purchase 137,777 shares of common stock exercisable within 60 days of December 31, 2017. |
|
| (2) | Includes 823,833 shares held by The Stasko Living Trust with respect to which Dr. Stasko and Jeanie Stasko serve as co-trustees and each has the power to vote and dispose of the shares held by the trust. |
|
| (3) | Based upon 15,990,658 shares of common stock outstanding as of November 7, 2017, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on November 9, 2017. Subsequent to the public offering that closed on January 9, 2018, this percentage would be 3.7% based upon 25,989,408 shares outstanding, as adjusted and reported by the Issuer in its Prospectus Supplement on Form 424(b)(5) filed on January 8, 2018. |
| (1) | Names of reporting persons
Jeanie Stasko | ||
| (2) | Check the appropriate box if a member of a group (see instructions)
(a) ☐ (b) ☐ | ||
| (3) | SEC use only
| ||
| (4) | Citizenship or place of organization
United States of America | ||
| Number of | (5) | Sole voting power
0 | |
| shares beneficially owned by | (6) | Shared voting power
823,833 (1) | |
| each reporting person | (7) | Sole dispositive power
0 | |
| with: | (8) | Shared dispositive power
823,833 (1) | |
| (9) | Aggregate amount beneficially owned by each reporting person
823,833 | ||
| (10) | Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
☐ | ||
| (11) | Percent of class represented by amount in Row (9)
5.2% (2) | ||
| (12) | Type of reporting person (see instructions)
IN | ||
|
| (1) | Includes 823,833 shares held by The Stasko Living Trust with respect to which Dr. Stasko and Jeanie Stasko serve as co-trustees and each has the power to vote and dispose of the shares held by the trust. |
|
| (2) | Based upon 15,990,658 shares of common stock outstanding as of November 7, 2017, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on November 9, 2017. Subsequent to the public offering that closed on January 9, 2018, this percentage would be 3.2% based upon 25,989,408 shares outstanding, as adjusted and reported by the Issuer in its Prospectus Supplement on Form 424(b)(5) filed on January 8, 2018. |
Item 1.
| (a) | Name of Issuer: |
Novan, Inc.
| (b) | Address of Issuer’s Principal Executive Offices: |
4105 Hopson Road, Morrisville, North Carolina 27560
Item 2
| (a) | Name of Person Filing: |
Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:
|
| 1. | Nathan Stasko, Ph.D.; and |
|
| 2. | Jeanie Stasko. |
| (b) | Address of Principal Business Office or, if none, Residence: |
The address of each Reporting Person is c/o Novan, Inc., 4105 Hopson Road, Morrisville, North Carolina 27560
| (c) | Citizenship: |
United States of America
| (d) | Title of Class of Securities: |
Common Stock, $0.0001 par value (“Common Stock”)
| (e) | CUSIP Number: |
66988N106
| Item 3. | If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not Applicable.
| Item 4. | Ownership. |
(a)-(c)
The ownership information presented below represents beneficial ownership of shares of Common Stock of the Issuer as of December 31, 2017, based upon 15,990,658 shares of common stock outstanding as of November 7, 2017, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on November 9, 2017. Subsequent to the offering that closed on January 9, 2018, Dr. and Mrs. Stasko are no longer the beneficial owners of more than five percent of the class of securities based upon 25,989,408 shares outstanding, as adjusted and reported by the Issuer in its Prospectus Supplement on Form 424(b)(5) filed on January 8, 2018.
Dr. and Mrs. Stasko are co-trustees and have shared dispositive and voting power with respect to 823,833 shares of Common Stock directly held by The Stasko Living Trust. In addition, Dr. Stasko has sole dispositive and voting power with respect to his
right to acquire 137,777 shares of Common Stock within 60 days of December 31, 2017 pursuant to the exercise of stock options. The beneficial ownership percentages for Dr. and Mrs. Stasko are set forth on their respective cover pages of this Schedule 13G.
| Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Not Applicable.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not Applicable.
| Item 8. | Identification and Classification of Members of the Group. |
Not Applicable.
| Item 9. | Notice of Dissolution of Group. |
Not Applicable.
| Item 10. | Certifications. |
Not Applicable.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Dated: February 14, 2018 |
|
|
|
|
|
| Nathan stasko, Ph.D. |
|
|
|
|
| /s/ Nathan Stasko, Ph.D. |
|
| Nathan Stasko, Ph.D. |
|
|
|
|
|
|
|
| Jeanie stasko |
|
|
|
|
| /s/ Jeanie Stasko |
|
| Jeanie Stasko |
LIST OF EXHIBITS
| Exhibit No. |
| Description |
| 99 |
| Joint Filing Agreement. |